Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer
Status:
Terminated
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with
stage III or stage IV pancreatic cancer.